Praxis Management Group Inc. announces Georgia market expansion and continued growth driven by its strategic partnership with AT&T. Read on to find out more.

“Megan’s leadership has been a significant driver of Praxis’s success to date,” said Mr. Souza. “As COO, she is uniquely positioned to guide Praxis through its next phase, driving disciplined ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Praxis Precision Medicines (PRAX) has drawn investor attention after recent share price moves, with the stock showing sharply different returns over the past year compared with its performance over ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

The early clinical evidence suggested ulixacaltamide could provide meaningful improvement over current therapies for ET ...

Praxis Precision Medicines’ challenge to Sage Therapeutics has unraveled. With a phase 2/3 clinical trial in major depressive disorder (MDD) failing comprehensively, Praxis is stopping work on a ...

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.